Team:Washington/Gram Positive/Design

From 2010.igem.org

(Difference between revisions)
(Circular Permutation of CapD)
(Circular Permutation of CapD)
Line 36: Line 36:
-
 
+
[[Image:CapDandCapDCPGell.jpg|thumb|400px|left|Left: CapD_CP as expected.  Right: CapD has ambiguous bands, making quantifying difficult and assay's less accurate]]
CapD_CP has one more crucial advantage over CapD.  When purifying CapD_CP, given our mass spec data, we can assume a massive majority of the purified CapD_CP is functional.  CapD, however, is a much more ambiguous case, as illustrated by our protein gel results.  The lower two bands of CapD correspond to the two subunits of cleaved CapD, which are active.  The upper band may be uncleaved, therefore unfunctional, CapD, or dimeric, active CapD that simply did not denature, or a combination of both.  Because of this, its difficult to quantify how much active protein is in a solution of purified CapD, making it difficult to assay.  For this reason, we made our active sight mutations to CapD_CP
CapD_CP has one more crucial advantage over CapD.  When purifying CapD_CP, given our mass spec data, we can assume a massive majority of the purified CapD_CP is functional.  CapD, however, is a much more ambiguous case, as illustrated by our protein gel results.  The lower two bands of CapD correspond to the two subunits of cleaved CapD, which are active.  The upper band may be uncleaved, therefore unfunctional, CapD, or dimeric, active CapD that simply did not denature, or a combination of both.  Because of this, its difficult to quantify how much active protein is in a solution of purified CapD, making it difficult to assay.  For this reason, we made our active sight mutations to CapD_CP
-
[[Image:CapDandCapDCPGell.jpg|thumb|400px|left]]
 
==Using FoldIt to Make a Better Hydrolase==
==Using FoldIt to Make a Better Hydrolase==

Revision as of 22:31, 15 September 2010

Making CapD a Better Anthrax Treatment

There are two main obstacles limiting natural CapD as an Anthrax therapeutic. First, natural CapD is a difficult to express dimer, requiring an auto-cleavage to activate. Second, CapD is a better transpeptidase than poly-γ-D-glutamate hydrolase, limiting its Anthrax decapsulating potential. To solve the first problem, we created a circular permuted, monomeric version of CapD that is easy to express and quantify. To improve hydrolosys, we used FoldIt, a computational toolbox, to design active sight mutations aimed to increase hydrolosis over transpeptidation.

Circular Permutation of CapD

When natural CapD is first translated, the key catalytic threonine residue is buried in the active site, inaccessible to poly-γ-D-glutamate. After auto-cleavage, this critical threonine becomes the new N terminus, which can take its place in the active site. By reordering the protein so the threonine is the first residue, and putting a FoldIt designed linker between the natural N and C terminus, we make a circular permutation of CapD that we named CapD_CP. CapD_CP is a monomer, historically easier to purify and more stable than dimers.

Schematic of natural CapD
Schematic of Circular Permutated CapD (CapD_CP)

Since the first residue of any nascent protein must be methionine, we rely on E. Coli’s naturally occurring methionine aminopeptidase to remove the first methionine, making CapD_CP catalytically active. The removal of the first methionine has been verified via mass spectrometry.

Expected weight of CapD_CP without Methionine=55285Da, with Methionine=55417Da. Our mass spec detected a peak at 55274.8Da (no Methionine) well within the 0.02% error limit for our mass spec


Left: CapD_CP as expected. Right: CapD has ambiguous bands, making quantifying difficult and assay's less accurate

CapD_CP has one more crucial advantage over CapD. When purifying CapD_CP, given our mass spec data, we can assume a massive majority of the purified CapD_CP is functional. CapD, however, is a much more ambiguous case, as illustrated by our protein gel results. The lower two bands of CapD correspond to the two subunits of cleaved CapD, which are active. The upper band may be uncleaved, therefore unfunctional, CapD, or dimeric, active CapD that simply did not denature, or a combination of both. Because of this, its difficult to quantify how much active protein is in a solution of purified CapD, making it difficult to assay. For this reason, we made our active sight mutations to CapD_CP

Using FoldIt to Make a Better Hydrolase

To increase the hydrolytic ability of CapD_CP, we made point mutations in the active site. We focused our attention on two types of mutations. First, we created point mutations that hydrogen bond to a modeled transition state of our substrate in an attempt to stabilize the transition state. Second, we mutated the active site into a more open and polar area in an attempt to increase the ease with which water can enter and participate in a hydrolysis reaction.

To make these point mutations, we used a program called FoldIt to predict how changes in protein structure and composition will affect protein stability. FoldIt provides a 3D representation of a protein's crystal structure which can be manipulated. Manipulation functions include point mutations, insertions, deletions, repacking of side chains, and backbone movement, which FoldIt then assesses for stability. This allows the user to quickly interact with a protein and easily predict how mutations will affect a protein.


Overview of Gram(+) Therapeutic       Building the Gram(+) Therapeutic